MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics
MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer clinical questions within the lung cancer continuum of care.
×
254 Results
MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer clinical questions within the lung cancer continuum of care.
Biodesix will acquire Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.
Biodesix will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib, and on the precision of liquid biopsy
Biodesix has entered into an agreement with Thermo Fisher Scientific.
Biodesix announced newly published data showing the noninvasive BDX-XL2 test could reduce the number of unnecessary biopsies carried out on patients with benign nodules
Biodesix presented positive data for a blood-based test with the potential to detect a non-small cell lung cancer (NSCLC) patient’s pre-treatment risk of anti-PD-1 immunotherapy resistance
Biodesix presented new data showing that the VeriStrat® test is predictive of outcomes for patients with non-small cell lung cancer treated with immune checkpoint inhibitors
Biodesix announced that it is collaborating with immune-oncology firm Immodulon Therapeutics to identify proteomic markers linked to pancreatic cancer.
Researchers with Biodesix and Genentech presented findings on a test designed to predict response to atezolizumab (Tecentriq®) in patients with non-small cell lung cancer (NSCLC)
Biodesix provided an update on the Observational Registry study to evaluate the impact of BDX-XL2 on physician decision making in routine clinical use (ORACLE)